- Home
- IDAI vs TOVX Comparison
IDAI vs TOVX Comparison
Compare IDAI & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- TOVX
- Stock Information
- Founded
- IDAI 2016
- TOVX 2001
- Country
- IDAI United States
- TOVX United States
- Employees
- IDAI N/A
- TOVX N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- TOVX Health Care
- Exchange
- IDAI Nasdaq
- TOVX Nasdaq
- Market Cap
- IDAI 4.6M
- TOVX 3.8M
- IPO Year
- IDAI N/A
- TOVX 2006
- Fundamental
- Price
- IDAI $2.66
- TOVX $0.43
- Analyst Decision
- IDAI
- TOVX Hold
- Analyst Count
- IDAI 0
- TOVX 1
- Target Price
- IDAI N/A
- TOVX N/A
- AVG Volume (30 Days)
- IDAI 37.6K
- TOVX 1.6M
- Earning Date
- IDAI 08-12-2025
- TOVX 08-12-2025
- Dividend Yield
- IDAI N/A
- TOVX N/A
- EPS Growth
- IDAI N/A
- TOVX N/A
- EPS
- IDAI N/A
- TOVX N/A
- Revenue
- IDAI $3,054,143.00
- TOVX N/A
- Revenue This Year
- IDAI $65.46
- TOVX N/A
- Revenue Next Year
- IDAI $12.00
- TOVX N/A
- P/E Ratio
- IDAI N/A
- TOVX N/A
- Revenue Growth
- IDAI N/A
- TOVX N/A
- 52 Week Low
- IDAI $1.43
- TOVX $0.40
- 52 Week High
- IDAI $18.75
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- IDAI 66.87
- TOVX 33.63
- Support Level
- IDAI $1.90
- TOVX $0.43
- Resistance Level
- IDAI $2.62
- TOVX $0.46
- Average True Range (ATR)
- IDAI 0.21
- TOVX 0.04
- MACD
- IDAI 0.05
- TOVX 0.02
- Stochastic Oscillator
- IDAI 96.34
- TOVX 15.54
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.